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Abstract 
Excessive glutamate release by glioma cells induces pharmacologically accessible neuronal 
hyperexcitation, including epilepsy. Two recent reports suggest that neuronal hyperexcitation 
stimulates bona fide glutamatergic synapses on glioma cells. Ionotropic glutamate receptors 
activate intercellular calcium signaling networks to orchestrate growth and invasion, 
presumably by facilitating oncogenic signaling cascades and cytoskeletal remodeling.  
 
Main text 
In the adult brain, neuronal activity induces neuroglial stem and progenitor cell proliferation 
and directs their migration via glutamatergic synapses. Two recent publications indicate that 
a similar mechanism may be hijacked by glioblastomas [1] and diffuse midline gliomas [2], 
two devastating malignant brain tumor entities with a generally fatal clinical course. 
Combined ultrastructural and electrophysiological studies identified bona fide glutamatergic 
synapses between neuronal axon terminals and post-synaptic glioma cells. In xenograft 
models, signaling through such neuron-glioma synapses promoted tumor growth and 
invasiveness whereas interference with synaptic transmission had cytostatic effects [1, 2]. 
Activation of post-synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-
type ionotropic glutamate receptors on glioma cells led to membrane depolarization and 
calcium influx. In normal brain cells the regulatory subunit GluA2 blocks calcium conductance 
of AMPA receptors. Adenosine-to-inosine editing of the Q/R site of the GluA2-encoding pre-
mRNA is required to encode this calcium-blocking property, but underediting in some glioma 
cells rendered AMPA receptors calcium permeable [1, 2].  
Non-synaptic spontaneous inward currents have also been identified in glioma cells. These 
smaller, but longer lasting potassium currents through inward rectifying channels are 
activated in response to potassium leakage from firing neurons and can trigger calcium 
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transients via voltage-gated conductances, albeit in a less efficient way than synaptic 
transmission [1, 2]. 
In normal neuronal tissues, N-methyl-D-aspartate (NMDA) type glutamate receptors are the 
major source of post-synaptic calcium currents. Continuous activation of NMDA receptors 
due to extensive glutamate secretion by glioblastoma cells can induce calcium-mediated 
neuronal apoptosis. By contrast, glioma cells are resistant to high extracellular glutamate 
concentrations because they lack significant levels of NMDA receptor expression [1, 2]. 
In gliomas, inward calcium transients propagate through intercellular networks via gap 
junctions [1, 2]. These networks are formed by cytoplasmic extensions termed tumor 
microtubes and have been proposed to convey growth signals and resistance to 
conventional chemoradiotherapy [3]. Most synapses between axonal endings and 
glioblastoma cells form along these tumor microtubes [1]. 
Of note, oligodendrogliomas, a less aggressive form of diffusely infiltrating glioma, do not 
form tumor microtube networks [3]. Nonetheless, single cell gene expression analyses 
identified expression of post-synaptic genes comparable to astrocytomas, suggesting 
alternative mechanisms of electric tumor cell activation [1]. Future studies will determine if 
and how neuronal activity exerts similar tumor propagating effects in non-astrocytic gliomas. 
Only approximately half of the cells in glioblastoma and diffuse midline glioma express post-
synaptic gene signatures, and neuron-glioma synapses are present on an even smaller 
proportion of cells [1, 2]. Single cell gene expression analyses of human diffuse midline 
gliomas identified a hierarchical cellular structure with a subpopulation of glioma cells 
characterized by enrichment of an oligodendrocyte precursor cell (OPC) signature [4]. 
Glioma cells exhibiting enrichment of this OPC signature also exhibited enriched expression 
of post-synaptic genes. These findings indicate that synapses between axons and glioma 
cells formed preferentially on undifferentiated cell populations, whereas the bulk of more 
differentiated tumor cells was widely devoid of post-synaptic gene expression [2]. Whether a 
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functional link between synaptic transmission and the stem-like phenotype exists remains to 
be determined.  
The identification of synaptic and non-synaptic electric interaction between neurons and 
glioma cells closes a loop of multifaceted pro-tumorigenic functions of glutamate in glioma 
biology (Figure 1). Extensive glutamate secretion by glioma cells via the cystine/glutamate 
exchanger system xc drives hyperexcitability of neurons in the tumor microenvironment [5], 
along with autocrine and paracrine stimulation of tumor cell growth and invasion via AMPA 
type glutamate receptors [6]. Enhanced neuronal activity promotes shedding of neuroligin-3 
into the synaptic cleft [7], which activates oncogenic signaling cascades and induces the 
expression of genes involved in synaptic transmission in glioma cells in a paracrine manner 
[8]. Subsequent synapse formation links neuronal hyperexcitability and epilepsy to tumor 
progression. 
Whether epilepsy is indeed an unfavorable predictor in glioma patients remains controversial. 
Exploring associations of epilepsy and patient survival is challenging and requires precise 
annotation of confounders that can skew results. For example, brain tumors presenting with 
epilepsy are more likely to be diagnosed at an early stage of the disease course when 
usually no symptoms other than epilepsy are present. Tumors associated with epilepsy may 
also be surgically better accessible, because proximity to the cerebral cortex is a pre-
requisite for the induction of seizures, and many epileptogenic brain areas such as the 
temporal or frontal cortex can be resected relatively safely. Epilepsy is also more frequent in 
patients with prognostically more favorable isocitrate dehydrogenase mutated gliomas. Vice 
versa, sub-clinical neuronal hyperexcitation may contribute to tumor progression 
independently of whether or not epileptic seizures occur. Anti-epileptic therapy with valproic 
acid or levetiracetam was not associated with outcome in a pooled secondary analysis of 
1’896 glioblastoma patients who were treated in four different randomized clinical trials [9], 
but this study did not account for the presence of epilepsy or other confounders mentioned 
further above. 
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Nonetheless, several clinically approved drugs could be repurposed to target the neuronal 
activity-driven tumor-propagating mechanism of gliomas (Figure 1). Lowering extracellular 
glutamate levels with the anti-epileptic drug and inhibitor of branched chain amino acid 
transaminase 1 (BCAT1) gabapentin [10], or with the anti-inflammatory drug sulfasalazine 
[5], an inhibitor of the cystine/glutamate antiporter system xc may reduce autocrine AMPA 
receptor activation, neuronal hyperexcitability and NMDA-mediated neuronal cell death. 
Neuroprotective NMDA inhibition can also be attempted with the anti-dementia drug 
memantine. The anti-epileptic drug perampanel, an inhibitor of AMPA-type glutamate 
receptors, and genetic modulation of AMPA type receptors exerted anti-invasive effects in 
xenograft models [1, 2]. Disruption of calcium networks by pharmacological inhibition of gap 
junctions utilizing the clinically approved anti-inflammatory drug meclofenamate likewise 
inhibited growth and migration mediated by synaptic transmission [2]. Lastly, neuroligin-3 
shedding can be targeted utilizing pharmacologic inhibitors of the sheddase ADAM10 (A 
Disintegrin And Metalloprotease Domain 10), thus preventing the activation of synaptic gene 
expression programs and direct activation of growth factor signaling cascades in glioma cells 
[8].  
In summary, a glutamate-driven vicious circle links neuronal hyperexcitation and epilepsy to 
tumor growth and conveys several drugable vulnerabilities of brain tumors for which very little 
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Figure 1. Pharmacologic targets at the neuron-glioma interface. Physiologically, 
neuronal action potentials depolarize synaptic end-feet, which activates voltage-gated 
calcium channels (not shown) to drive neurotransmitter release into the synaptic cleft. The 
excitatory neurotransmitter glutamate binds post-synaptic AMPA and kainate type ionotropic 
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receptors, which conduct sodium inward and potassium outward currents, resulting in 
membrane depolarization. The GluA2 subunit of AMPA type receptors prevents calcium 
influx in neurons, and upon combined repetitive chemical stimulation and membrane 
depolarization, calcium currents through slow-kinetics NMDA type receptors are activated to 
promote synapse formation between neurons (not shown). Excessive BCAT1-dependent 
glutamate secretion by glioma cells through the glutamate/cystine antiporter system Xc 
promotes neuronal hyperexcitability, which can result in epilepsy and may induce calcium-
mediated neuronal apoptosis via overactivation of NMDA-type glutamate receptors. Glioma 
cells lack NMDA receptors, but express calcium-conducting AMPA receptors that are 
stimulated by glutamate in an autocrine and paracrine fashion to promote tumor growth and 
invasion, presumably through activation of oncogenic signaling cascades and cytoskeletal 
remodeling. Neuronal activity also promotes shedding of neuroligin-3, which activates 
oncogenic signaling cascades including the focal adhesion kinase (FAK) and 
phosphoinositide 3-kinase (PI3K) pathways, and drives synaptic gene expression in glioma 
cells in a paracrine manner by acting on one or several unknown receptors. Glioma cells are 
interconnected in a tubular network by gap junctions. Glutamatergic synapses form on tumor 
microtubes and activate calcium-conducting AMPA receptors. Calcium signals of tumor cells 
may thus be propagated to connected cells, further driving growth and invasion. Several 
pharmacologic inhibitors of different nodes of this neuron-glioma interface are clinically 
approved for other indications (red writing). 
 
 

